HTA Planning and Reimbursement Evidence Strategy

Strengthen HTA dossier and strategy to OPTIMIZE HTA Success

HTA Planning & Reimbursement Evidence Strategy

At MORSE Consulting, we leverage our real-world experience, technical skill, and nuanced understanding of the Canadian payer & HTA context to provide expert guidance on HTA assessment and (re)submission strategies throughout your product launch life cycle. As Canada’s leading experts on the pCPA, HTA approach, and pharmaceutical value strategy, we deliver insights into the subtleties of Canadian market influencers and payers’ views on value. Our services include Health Economics and Outcomes Research (HEOR) work developing and strengthening pharmacoeconomic model strategies, informing pipeline clinical trial development and real world evidence (RWE) planning from the lens of the needs for both HTA and payers, conducting thorough HTA dossier and strategy reviews, and facilitating advisory boards with key opinion leaders. With our HTA planning and reimbursement evidence strategy advice, you can navigate and OPTIMIZE the complex HTA landscape with confidence.

HTA Planning and Reimbursement Evidence Strategy